Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Proto-Oncogene Proteins c-ret | 3 | 2024 | 33 | 1.290 |
Why?
|
| Protein Kinase Inhibitors | 3 | 2024 | 206 | 1.150 |
Why?
|
| Receptor, trkA | 1 | 2024 | 7 | 0.950 |
Why?
|
| Indoles | 1 | 2024 | 278 | 0.770 |
Why?
|
| Antineoplastic Agents | 4 | 2024 | 1186 | 0.750 |
Why?
|
| E1A-Associated p300 Protein | 1 | 2020 | 9 | 0.740 |
Why?
|
| Pyridones | 1 | 2020 | 34 | 0.730 |
Why?
|
| Benzimidazoles | 1 | 2020 | 49 | 0.720 |
Why?
|
| Proteins | 1 | 2020 | 345 | 0.600 |
Why?
|
| rho GTP-Binding Proteins | 2 | 2015 | 6 | 0.540 |
Why?
|
| Keratinocytes | 2 | 2012 | 90 | 0.490 |
Why?
|
| Desmoplakins | 1 | 2012 | 3 | 0.410 |
Why?
|
| Drug Discovery | 2 | 2024 | 88 | 0.400 |
Why?
|
| Cell Line, Tumor | 4 | 2024 | 1416 | 0.370 |
Why?
|
| Apoptosis | 2 | 2015 | 1112 | 0.290 |
Why?
|
| Molecular Structure | 2 | 2024 | 296 | 0.260 |
Why?
|
| Structure-Activity Relationship | 2 | 2024 | 401 | 0.260 |
Why?
|
| Cell Survival | 2 | 2020 | 602 | 0.250 |
Why?
|
| Pyrimidines | 1 | 2024 | 193 | 0.210 |
Why?
|
| rho-Associated Kinases | 2 | 2012 | 20 | 0.200 |
Why?
|
| Cell Cycle | 2 | 2020 | 232 | 0.200 |
Why?
|
| Cell Proliferation | 3 | 2021 | 1013 | 0.200 |
Why?
|
| Adenine | 1 | 2021 | 32 | 0.190 |
Why?
|
| Interferon Regulatory Factors | 1 | 2020 | 17 | 0.190 |
Why?
|
| Proto-Oncogene Proteins c-myc | 1 | 2020 | 50 | 0.180 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2021 | 1378 | 0.180 |
Why?
|
| Pyrazoles | 1 | 2021 | 114 | 0.180 |
Why?
|
| Leukemia, Plasma Cell | 1 | 2020 | 33 | 0.180 |
Why?
|
| Genes, myc | 1 | 2019 | 41 | 0.160 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2020 | 314 | 0.160 |
Why?
|
| RNA, Small Interfering | 2 | 2015 | 215 | 0.130 |
Why?
|
| Humans | 9 | 2024 | 50208 | 0.130 |
Why?
|
| Multiple Myeloma | 2 | 2020 | 2954 | 0.120 |
Why?
|
| Glioma | 1 | 2015 | 79 | 0.120 |
Why?
|
| Gene Regulatory Networks | 1 | 2015 | 107 | 0.120 |
Why?
|
| Neoplasm Invasiveness | 1 | 2015 | 266 | 0.120 |
Why?
|
| Mutation | 1 | 2020 | 1294 | 0.120 |
Why?
|
| gamma Catenin | 1 | 2012 | 1 | 0.100 |
Why?
|
| Desmosomes | 1 | 2012 | 3 | 0.100 |
Why?
|
| Adherens Junctions | 1 | 2012 | 4 | 0.100 |
Why?
|
| Focal Adhesions | 1 | 2012 | 14 | 0.100 |
Why?
|
| Amides | 1 | 2012 | 39 | 0.100 |
Why?
|
| Cell Communication | 1 | 2012 | 69 | 0.100 |
Why?
|
| Brain Neoplasms | 1 | 2015 | 288 | 0.100 |
Why?
|
| Transfection | 1 | 2012 | 355 | 0.100 |
Why?
|
| Neoplasms | 1 | 2021 | 1249 | 0.100 |
Why?
|
| Pyridines | 1 | 2012 | 131 | 0.090 |
Why?
|
| Cisplatin | 1 | 2012 | 278 | 0.090 |
Why?
|
| Cell Line | 1 | 2012 | 1021 | 0.080 |
Why?
|
| Translocation, Genetic | 2 | 2020 | 264 | 0.080 |
Why?
|
| Gene Expression Regulation | 1 | 2012 | 979 | 0.070 |
Why?
|
| Time Factors | 1 | 2012 | 2922 | 0.060 |
Why?
|
| Cell Movement | 2 | 2015 | 249 | 0.050 |
Why?
|
| Gene Expression Regulation, Leukemic | 1 | 2020 | 33 | 0.050 |
Why?
|
| Mutation Rate | 1 | 2020 | 36 | 0.050 |
Why?
|
| Protein Disulfide-Isomerases | 1 | 2019 | 14 | 0.040 |
Why?
|
| Genes, Immunoglobulin Heavy Chain | 1 | 2019 | 13 | 0.040 |
Why?
|
| Clinical Trials as Topic | 1 | 2021 | 466 | 0.040 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2019 | 259 | 0.040 |
Why?
|
| Genomics | 1 | 2020 | 285 | 0.040 |
Why?
|
| Transcriptome | 1 | 2020 | 320 | 0.040 |
Why?
|
| Gene Expression Profiling | 1 | 2020 | 1037 | 0.030 |
Why?
|
| DNA Copy Number Variations | 1 | 2015 | 110 | 0.030 |
Why?
|
| RNA Interference | 1 | 2015 | 179 | 0.030 |
Why?
|
| HEK293 Cells | 1 | 2015 | 224 | 0.030 |
Why?
|
| Aged, 80 and over | 1 | 2020 | 3154 | 0.030 |
Why?
|
| Focal Adhesion Protein-Tyrosine Kinases | 1 | 2012 | 20 | 0.030 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2015 | 828 | 0.020 |
Why?
|
| Aged | 1 | 2020 | 9405 | 0.020 |
Why?
|
| Animals | 1 | 2021 | 13246 | 0.020 |
Why?
|
| Middle Aged | 1 | 2020 | 12206 | 0.020 |
Why?
|
| Signal Transduction | 1 | 2012 | 1622 | 0.020 |
Why?
|
| Adult | 1 | 2020 | 13324 | 0.010 |
Why?
|
| Male | 1 | 2020 | 25399 | 0.010 |
Why?
|
| Female | 1 | 2020 | 26635 | 0.010 |
Why?
|